HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 29/3/469    most recent 09031936.00081706v1 Alert me when this article is cited Alert me if a correction is posted Permissions Request Permissions Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (21) Citing Articles via Google Scholar Google Scholar Articles by Mathai, S. C. Articles by Hassoun, P. M. Search for Related Content PubMed PubMed Citation Articles by Mathai, S. C. Articles by Hassoun, P. M.

Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension

¹ Division of Pulmonary and Critical Care Medicine and, ³ Cardiology, Dept of Medicine, Johns Hopkins University, Baltimore, MD, and ² Division of Pulmonary and Critical Care Medicine, Dept of Medicine, Emory University, Atlanta, GA, USA.

CORRESPONDENCE: P. M. Hassoun, Johns Hopkins University, Division of Pulmonary and Critical Care Medicine, 1830 East Monument Street, 5th Floor, Baltimore, MD 21205, USA. Fax: 1 4109550036. E-mail: phassoun{at}jhmi.edu

Keywords: Bosentan, combination therapy, pulmonary hypertension, scleroderma, sildenafil

Received: June 22, 2006
Accepted October 22, 2006

Combination therapy has been recommended for the treatment of pulmonary arterial hypertension (PAH). However, there is scant information on combination therapy after failure of monotherapy, particularly in patients with scleroderma-associated PAH (PAH-SSD).

From a group of 82 consecutive patients with PAH who received initial bosentan monotherapy, a total of 13 idiopathic PAH (IPAH) and 12 PAH-SSD patients requiring additional therapy with sildenafil were studied. Sildenafil was added for clinical deterioration based upon symptoms, New York Heart Association (NYHA) classification or 6-min walk distance (6MWD). Clinical data and haemodynamics were collected at baseline. Assessments were made at 1–3-month intervals.

At baseline, there were no differences in demographics, NYHA classification, haemodynamics or 6MWD between the two groups. After initiation of bosentan, both groups experienced clinical improvement but ultimately deteriorated (median time to monotherapy failure 792 versus 458 days for IPAH and PAH-SSD patients, respectively). After addition of sildenafil, more IPAH patients tended to improve in NYHA class (five out of 13 versus two out of 12) and walked further (mean difference in 6MWD 47±77 m versus -7±40 m) compared with PAH-SSD patients.

In conclusion, addition of sildenafil after bosentan monotherapy failure improved New York Heart Association class and 6-min walk distance in idiopathic pulmonary arterial hypertension patients but failed to improve either parameter in scleroderma-associated pulmonary arterial hypertension patients. Additional studies are needed to assess the tolerability and efficacy of this combination in patients with scleroderma-associated pulmonary arterial hypertension.

This article has been cited by other articles:

				E. Gruenig, E. Michelakis, J.-L. Vachiery, C. D. Vizza, F. J. Meyer, M. Doelberg, D. Bach, J. Dingemanse, and N. Galie Acute Hemodynamic Effects of Single-Dose Sildenafil When Added to Established Bosentan Therapy in Patients With Pulmonary Arterial Hypertension: Results of the COMPASS-1 Study J. Clin. Pharmacol., November 1, 2009; 49(11): 1343 - 1352. [Abstract] [Full Text] [PDF]

				Authors/Task Force Members, N. Galie, M. M. Hoeper, M. Humbert, A. Torbicki, J.-L. Vachiery, J. A. Barbera, M. Beghetti, P. Corris, S. Gaine, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT) Eur. Heart J., October 2, 2009; 30(20): 2493 - 2537. [Full Text] [PDF]

				N. Galie, L. Negro, and G. Simonneau The use of combination therapy in pulmonary arterial hypertension: new developments Eur. Respir. Rev., September 1, 2009; 18(113): 148 - 153. [Abstract] [Full Text] [PDF]

				M. J. Overbeek, M. C. Vonk, A. Boonstra, A. E. Voskuyl, A. Vonk-Noordegraaf, E. F. Smit, B. A. C. Dijkmans, P. E. Postmus, W. J. Mooi, Y. Heijdra, et al. Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy Eur. Respir. J., August 1, 2009; 34(2): 371 - 379. [Abstract] [Full Text] [PDF]

				K. Kuwano, A. Hashino, K. Noda, K. Kosugi, and K. Kuwabara A Long-Acting and Highly Selective Prostacyclin Receptor Agonist Prodrug, 2-{4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), Ameliorates Rat Pulmonary Hypertension with Unique Relaxant Responses of Its Active Form, {4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic Acid (MRE-269), on Rat Pulmonary Artery J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 691 - 699. [Abstract] [Full Text] [PDF]

				K. Boutet, D. Montani, X. Jais, A. Yaici, O. Sitbon, G. Simonneau, and M. Humbert Review: Therapeutic advances in pulmonary arterial hypertension Therapeutic Advances in Respiratory Disease, August 1, 2008; 2(4): 249 - 265. [Abstract] [PDF]

				M. R. Wilkins, J. Wharton, F. Grimminger, and H. A. Ghofrani Phosphodiesterase inhibitors for the treatment of pulmonary hypertension Eur. Respir. J., July 1, 2008; 32(1): 198 - 209. [Abstract] [Full Text] [PDF]

				M. A. Mathier, J. Zhang, and R. C. Ramanathan Dramatic Functional Improvement Following Bariatric Surgery in a Patient With Pulmonary Arterial Hypertension and Morbid Obesity Chest, March 1, 2008; 133(3): 789 - 792. [Abstract] [Full Text] [PDF]

				National Pulmonary Hypertension Centres of the UK Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland Heart, March 1, 2008; 94(Suppl_1): i1 - i41. [Full Text] [PDF]

				National Pulmonary Hypertension Centres of the UK Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland Thorax, March 1, 2008; 63(Suppl_2): ii1 - ii41. [Full Text] [PDF]

				J. Dupuis and M. M. Hoeper Endothelin receptor antagonists in pulmonary arterial hypertension Eur. Respir. J., February 1, 2008; 31(2): 407 - 415. [Abstract] [Full Text] [PDF]

				G. V. Ramani, L. Cadaret, J. Zhang, R. Ramanathan, and M. A. Mathier DRAMATIC FUNCTIONAL IMPROVEMENT FOLLOWING BARIATRIC SURGERY IN A MORBIDLY OBESE PATIENT WITH PULMONARY ARTERIAL HYPERTENSION Chest Meeting Abstracts, October 1, 2007; 132(4): 730 - 730. [Abstract] [PDF]

				R. J. Oudiz, G. Roveran, J. E. Hansen, X.-G. Sun, and K. Wasserman Effect of sildenafil on ventilatory efficiency and exercise tolerance in pulmonary hypertension Eur J Heart Fail, September 1, 2007; 9(9): 917 - 921. [Abstract] [Full Text] [PDF]

				M. M. Hoeper Observational trials in pulmonary arterial hypertension: low scientific evidence but high clinical value Eur. Respir. J., March 1, 2007; 29(3): 432 - 434. [Full Text] [PDF]